Clinical TrialMay 12, 2026, 09:32 AM
Evaxion to present new EVX-04 data for AML vaccine at EHA 2026 Congress
AI Summary
Evaxion A/S announced it will present new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), at the European Hematology Association (EHA) 2026 Congress in June. The data will focus on the functional characterization of EVX-04, an AI-designed vaccine targeting endogenous retroviral antigens. This presentation signifies a crucial step towards clinical testing, with the company planning to submit a clinical trial application in the second half of 2026.
Key Highlights
- Evaxion to present new preclinical data for EVX-04, an off-the-shelf AML vaccine, at EHA 2026 Congress.
- The data will detail the functional characterization of EVX-04.
- EVX-04 is an AI-designed therapeutic vaccine targeting endogenous retroviral antigens.
- Presentation is scheduled for June 13, 2026, at 18:45-19:45 CET.
- Evaxion plans to submit a clinical trial application for EVX-04 in H2 2026.
- Preclinical models show EVX-04 elicits a specific immune response and prevents tumor growth.
Price Impact
More from EVAX